41
Participants
Start Date
February 28, 2006
Primary Completion Date
December 1, 2010
Study Completion Date
December 31, 2010
O6-benzylguanine
Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
temozolomide
Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
Children's Hospital of Pittsburgh, Pittsburgh
Duke Comprehensive Cancer Center, Durham
St. Jude Children's Research Hospital, Memphis
Children's Memorial Hospital - Chicago, Chicago
Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Children's Hospital and Regional Medical Center - Seattle, Seattle
Children's National Medical Center, Washington D.C.
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston
Children's Hospital of Philadelphia, Philadelphia
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston
National Cancer Institute (NCI)
NIH